BIS-guided Fluid Management in HD Patients
Effects of Bioimpedance-guided Fluid Management in Maintenance Hemodialysis Patients -
1 other identifier
interventional
110
1 country
1
Brief Summary
Hemodialysis (HD) is life-sustaining in kidney failure. However, adequate fluid status depends on precise estimation of dry weight (DW), which is a goal difficult to achieve. This randomized open label controlled parallel-group trial aims to compare spectroscopy bioimpedance (BIS) guided DW estimation with clinical evaluation alone. Maintenance HD patients above 18 years old were randomized to monthly clinical evaluation (CE) alone or added to twice a year BIS-guided DW estimation. Randomization was performed through random number table. Follow-up lasted up to two years. Primary outcome was survival time and secondary outcomes were rate of hospital admissions, systolic and diastolic blood pressure (BP) change and number of prescribed antihypertensive drugs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2019
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2021
CompletedFirst Submitted
Initial submission to the registry
February 28, 2022
CompletedFirst Posted
Study publicly available on registry
March 9, 2022
CompletedMarch 24, 2022
March 1, 2022
2 years
February 28, 2022
March 8, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Survival
Survival curve
two years
Secondary Outcomes (3)
Hospital Admissions
two years
Systolic and Diastolic Blood pressure
two years
Anti-hypertensive medication
two years
Study Arms (2)
BIS Group
EXPERIMENTALDry weight is evaluated monthly by clinical examination and biannually BIS-guided.
CE Group
ACTIVE COMPARATORDry weight is evaluated monthly by clinical examination alone.
Interventions
Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).
The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.
Eligibility Criteria
You may qualify if:
- CKD diagnosis,
- years or older,
- treated by in-center HD for longer than three months,
- HD treatment in the Dialysis and Transplantation unit of a Brazilian University Hospital.
You may not qualify if:
- less than thrice a week HD session,
- lower limbs amputation,
- pregnancy,
- pacemaker, implantable cardioverter-defibrillator or orthopedic protheses use.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Universitário São Francisco de Paula
Pelotas, Rio Grande do Sul, 96020-260, Brazil
Related Publications (1)
Stigger K, Ribeiro LR, Cordeiro FM, Bohlke M. Incidence of hospital admissions in bioimpedance-guided fluid management among maintenance hemodialysis patients-Results of a randomized controlled trial. Hemodial Int. 2023 Jul;27(3):318-325. doi: 10.1111/hdi.13076. Epub 2023 Apr 17.
PMID: 37067785DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
February 28, 2022
First Posted
March 9, 2022
Study Start
September 1, 2019
Primary Completion
September 1, 2021
Study Completion
September 1, 2021
Last Updated
March 24, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
- Time Frame
- After conclusion of publication process
- Access Criteria
- Public
After publication, include data in a data repository (Harvard Dataverse)